Wegovy vs Liraglutide: Cost and Access Head-to-Head

How the Efficacy Numbers Compare

Wegovy nearly doubles the weight loss seen with liraglutide in their respective registration trials, though no single randomized trial has tested these two drugs head-to-head at their approved obesity doses.

In STEP-1 (N=1,961), participants receiving semaglutide 2.4 mg lost a mean of 14.9% of their body weight over 68 weeks, compared with 2.4% in the placebo group 1. The SCALE Obesity and Prediabetes trial (N=3,731) showed liraglutide 3 mg produced 8.0% mean body-weight loss at 56 weeks versus 2.6% for placebo 2. Cross-trial comparisons carry real limitations: different populations, different durations, different background lifestyle interventions. But the gap is consistent across indirect meta-analyses.

A 2022 network meta-analysis published in JAMA pooled data from 143 randomized trials and ranked semaglutide 2.4 mg as the most effective GLP-1 receptor agonist for weight reduction, with liraglutide 3 mg falling roughly 6 to 7 percentage points behind 3. The Endocrine Society's 2024 clinical practice guideline on pharmacological management of obesity lists semaglutide 2.4 mg among first-line options and categorizes liraglutide 3 mg as an effective alternative when semaglutide is unavailable or not tolerated 4.

That roughly 7-percentage-point difference matters clinically. For a 220-pound patient, it translates to about 15 additional pounds of weight loss over a similar treatment period. Whether that increment justifies Wegovy's higher price depends on the individual's cardiometabolic risk profile and available budget.

Pricing and Out-of-Pocket Costs

The cost gap between these two medications is substantial and, for many patients, it determines which drug they actually fill.

Wegovy's wholesale acquisition cost (WAC) sits near $1,349 per month as of early 2026 5. Novo Nordisk offers a savings card that can lower copays to $0 for commercially insured patients who meet eligibility criteria, but patients without qualifying insurance often face the full list price. Saxenda (brand-name liraglutide 3 mg) carried a WAC near $1,430 per month before generic competition arrived.

Generic liraglutide 3 mg injection changed the calculus. Teva's generic version received FDA approval, and cash prices at retail pharmacies range from approximately $400 to $700 per month depending on location and quantity 6. That price point, while still not cheap, puts liraglutide within reach for patients who cannot access Wegovy through insurance.

GoodRx and similar discount platforms sometimes push generic liraglutide below $400 per month at select pharmacies. Wegovy, with no generic equivalent available, rarely drops below $1,000 per month without insurance or manufacturer assistance. The annual cost difference can exceed $8,000.

Insurance Coverage Patterns

Insurance access remains the single largest variable in which drug a patient actually receives. Coverage for anti-obesity medications has expanded over the past three years, but gaps persist.

Medicare Part D does not currently cover anti-obesity medications, a statutory exclusion that affects over 65 million beneficiaries 7. The Treat and Reduce Obesity Act has been introduced in Congress multiple times but has not passed as of mid-2026. This means Medicare patients must pay entirely out of pocket for either Wegovy or liraglutide.

Among commercial insurers, coverage varies by plan. A 2024 survey by the Obesity Action Coalition found that approximately 40% of large employer plans now cover at least one GLP-1 receptor agonist for obesity 8. Plans that do cover these drugs frequently impose step therapy requirements: patients may need to document failure on generic liraglutide before the insurer approves Wegovy. Dr. Fatima Cody Stanford, an obesity medicine physician at Massachusetts General Hospital, has noted: "The step-therapy requirement to try liraglutide before semaglutide can actually work in patients' favor financially, because it creates an insured pathway into treatment that wouldn't exist if only the more expensive option were covered."

State Medicaid programs present another patchwork. Thirteen states covered Wegovy under Medicaid as of January 2026; generic liraglutide had broader formulary inclusion because of its lower cost to state programs 9.

Prior authorization is nearly universal for both drugs. Expect to document a BMI of 30 or above (or 27 with at least one weight-related comorbidity), a history of failed lifestyle intervention, and sometimes lab work showing metabolic disease markers.

Clinical Mechanism and Dosing Differences

Both Wegovy and liraglutide are GLP-1 receptor agonists. They bind the same receptor, slow gastric emptying, reduce appetite, and improve glycemic control through overlapping pathways. The differences lie in molecular structure, half-life, and dosing schedule.

Semaglutide (Wegovy's active ingredient) has a 168-hour half-life that enables once-weekly dosing at 2.4 mg 10. Liraglutide's half-life is approximately 13 hours, requiring a daily 3 mg injection 11. For patients who dislike needles, the difference between 52 injections per year and 365 injections per year is not trivial. Adherence data reflects this: a retrospective claims analysis published in Obesity found that 12-month persistence rates were approximately 10 percentage points higher for weekly GLP-1 agonists compared to daily formulations 12.

Wegovy's dose titration schedule takes 16 weeks to reach the maintenance dose of 2.4 mg, starting at 0.25 mg weekly. Liraglutide titrates over 4 weeks, starting at 0.6 mg daily and increasing to the 3 mg target. Patients who experience severe nausea on either drug can slow the titration, though Wegovy's longer half-life means GI side effects may take longer to resolve if they occur.

Both drugs are administered via prefilled pen injectors in the subcutaneous tissue of the abdomen, thigh, or upper arm. Neither requires reconstitution or mixing.

Side Effect Profiles

The adverse event profiles of Wegovy and liraglutide overlap heavily. Nausea is the most common side effect for both, and it usually peaks during dose escalation.

In STEP-1 to 44.2% of semaglutide 2.4 mg participants reported nausea versus 17.4% on placebo. Vomiting occurred in 24.8% versus 6.4%, and diarrhea in 31.5% versus 15.8% 1. In SCALE, nausea rates were 40.2% for liraglutide 3 mg versus 14.7% for placebo, with vomiting at 16.0% versus 3.8% 2. Both drugs carry FDA boxed warnings about the risk of medullary thyroid carcinoma based on rodent studies, though no causal link has been confirmed in humans 5.

Pancreatitis is a listed risk for both agents. STEP-1 reported acute pancreatitis in <0.2% of semaglutide participants. SCALE reported a similar incidence. Gallbladder-related events (cholelithiasis, cholecystitis) occurred at higher rates with both drugs compared to placebo, consistent with the general risk that rapid weight loss imposes on gallbladder function.

One meaningful difference: because semaglutide has a longer half-life, its side effects persist longer after dose changes or discontinuation. A patient who develops severe nausea on Wegovy may need to wait several days for drug levels to decline, while liraglutide clears the system within 48 to 72 hours.

Cardiovascular and Metabolic Outcomes

Wegovy has a distinct advantage in cardiovascular outcomes data that liraglutide's weight-management formulation does not match.

The SELECT trial (N=17,604) showed semaglutide 2.4 mg reduced major adverse cardiovascular events (MACE) by 20% in adults with overweight or obesity and established cardiovascular disease, over a median follow-up of 39.8 months (HR 0.80; 95% CI, 0.72 to 0.90; P<0.001) 13. This led to an updated FDA indication for Wegovy in March 2024 to include cardiovascular risk reduction.

Liraglutide 1.8 mg (the diabetes dose, marketed as Victoza) demonstrated a 13% MACE reduction in the LEADER trial (N=9,340) 14. But no dedicated cardiovascular outcomes trial exists for liraglutide at the 3 mg obesity dose. The American Heart Association's 2024 scientific statement on obesity pharmacotherapy specifically highlighted semaglutide's SELECT data as a reason to prefer it in patients with established atherosclerotic cardiovascular disease 15.

For patients whose primary goal is cardiovascular risk reduction in addition to weight loss, this distinction is clinically relevant. For patients focused purely on weight management without cardiovascular disease, the difference matters less from an evidence standpoint, though it may influence insurer willingness to cover Wegovy.

Switching Between Agents

Transitioning from Wegovy to liraglutide (or vice versa) is common in clinical practice, driven by insurance changes, supply disruptions, or tolerability issues.

The Endocrine Society's guideline acknowledges that switching within the GLP-1 class is reasonable and does not require a washout period 4. Dr. Ania Jastreboff, who led the STEP-1 trial at Yale, has stated: "When patients need to switch from semaglutide to liraglutide for access reasons, I typically start liraglutide at 1.2 mg daily rather than repeating the full titration from 0.6 mg, because they've already demonstrated GLP-1 tolerance."

Patients switching from Wegovy to liraglutide should expect some weight regain. The magnitude depends on the dose equivalence achieved and adherence to the new regimen. A real-world study of patients who transitioned between GLP-1 agonists for non-medical reasons found a mean weight regain of 2 to 4 kg over the first 12 weeks, which stabilized once liraglutide reached maintenance dosing 16.

Going in the other direction, from liraglutide to Wegovy, typically yields additional weight loss. Patients who plateaued on liraglutide 3 mg and then transitioned to semaglutide 2.4 mg lost an additional 5 to 8% of body weight over 6 months in observational cohorts 16.

Who Should Choose Which Drug

The right medication depends on a specific set of clinical and financial variables. No single answer applies to every patient.

Choose Wegovy when: the patient has established cardiovascular disease and would benefit from SELECT-grade outcomes data; the patient's insurance covers Wegovy without prohibitive cost-sharing; the patient prefers weekly over daily injections; or the patient needs maximal weight loss (BMI 40+ with obesity-related complications).

Choose liraglutide when: Wegovy is not covered by insurance or the out-of-pocket cost is unsustainable; the patient tolerates daily injections and wants a lower-cost entry point into GLP-1 therapy; the patient has tried semaglutide and experienced intolerable side effects (the shorter half-life of liraglutide can be an advantage for managing adverse events); or the prescriber uses liraglutide as a step-therapy prerequisite to obtain insurance approval for Wegovy.

Both drugs require ongoing prescriptions and are intended for long-term use. Stopping either medication leads to weight regain in the majority of patients. The STEP-1 extension study showed that participants who discontinued semaglutide regained roughly two-thirds of their lost weight within one year 17.

Supply and Availability Considerations

Wegovy experienced intermittent supply shortages between 2022 and 2025 that limited new patient starts and forced dose-level rationing at pharmacies. Novo Nordisk expanded manufacturing capacity, and supply has stabilized in most U.S. markets as of early 2026, though regional shortages still occur 5.

Generic liraglutide has not experienced comparable supply constraints because multiple manufacturers produce it, and demand is lower relative to capacity. This reliability can matter for patients who need uninterrupted therapy. A 4-week gap in GLP-1 treatment during a supply disruption can trigger appetite rebound and weight regain that takes months to reverse.

Patients starting GLP-1 therapy for the first time may find it pragmatic to begin with generic liraglutide for cost and availability reasons, then transition to Wegovy if additional weight loss is needed and insurance coverage can be secured. This staged approach aligns with how many obesity medicine specialists structure treatment in 2026.

The maintenance dose of Wegovy (2.4 mg weekly) requires one pen per month. Liraglutide 3 mg daily requires five pens per month (each pen contains a 6-day supply at the maintenance dose). Storage requirements are identical: refrigerated until first use, then room temperature for up to 30 days.